Despite modest therapeutic advances in the past decade, the prognosis of malignant pleural mesothelioma (MPM), an aggressive cancer associated with previous asbestos exposure, remains grim ([@bib30]). However, it has also been recognised that some MPM patients may survive substantially longer than the median survival time of 9--12 months ([@bib43]; [@bib9]; [@bib21]).

Evidence on factors associated with prolonged survival is largely drawn from studies investigating series of patients receiving chemotherapy or radical surgery. Analyses of pooled clinical trial data have demonstrated the prognostic impact of certain demographic variables (age and gender), clinical and pathological data (haemoglobin levels, leukocyte and platelet counts and performance status) and tumour characteristics (histological subtype) leading to the development of two scoring systems, one developed by the European Organisation for Research and Treatment of Cancer (EORTC) and the other by the Cancer and Leukaemia Group B (CALGB) ([@bib12]; [@bib22]; [@bib14]; [@bib31]). However, these systems do not include more recently identified prognostic factors, such as clinical stage at diagnosis ([@bib1]), hypo-albuminaemia ([@bib32]) and the neutrophil--lymphocyte ratio (NLR) ([@bib26]; [@bib24]). Non-randomised studies in MPM patients who received radical surgery revealed that clinical stage, histological subtype and the use of pemetrexed-based chemotherapy were associated with longer-term survival ([@bib15]; [@bib48]).

Here we report results from analyses of a database of all MPM patients diagnosed in 2002--2009 who received compensation for occupational exposure to asbestos in New South Wales, Australia. We assessed a range of demographic, clinical and pathological, tumour and treatment factors associated with longer-term survival in this large series of patients. In addition, we developed a risk score that may better identify patients likely to have longer survival.

Materials and methods
=====================

The Sydney Local Health District Ethics Committee approved this study.

Patient data
------------

The Workers\' Compensation Dust Diseases Board (DDB) collect comprehensive data on patients who contracted MPM as a result of their employment in New South Wales (NSW). It is estimated that this represents approximately 70% of all MPM cases recorded on the NSW Cancer Registry for the same period. We identified patients who registered with the DDB between 1 January 2002 to 31 December 2009 who had a confirmed diagnosis of MPM, based on detailed clinical, pathological, radiological and occupational histories. NSW death certificate data were linked to the DDB records. Mortality follow-up was ascertained up to 27 June 2012. Clinical and occupational histories were obtained from the DDB database. Where incomplete, missing data were sought from the treating physicians, surgeons and general practitioners.

Demographic data collected included sex, age at diagnosis, residential location at registration, smoking status, age at first asbestos exposure and occupational history. Residential location was classified according to the Australian Standard Geographical Classification---Remoteness Classification ([@bib3]). We estimated cumulative years of occupational asbestos exposure using a patients\' occupational history and their first age of asbestos exposure. Performance status was noted according to Eastern Cooperative Performance Group (ECOG) criteria and dichotomised according to EORTC prognostic classification (ECOG 0 *vs* ⩾1) ([@bib12]). Where not formally documented, patients were classified as ⩾1 when clinical symptoms (pain, dyspnoea, cough or lethargy) were recorded. Results of blood tests taken within 30 days of diagnosis, pathology reports (at the time of diagnosis or surgery) and radiological data (CT imaging to estimate clinical stage according to AJCCC criteria ([@bib10])) were reviewed.

Statistical analysis
--------------------

The prognostic value of variables was first assessed using log-rank analysis and then with adjustment for other covariates in multivariable Cox regression models. Survival was defined as the time from diagnosis to death or the end of follow-up.

Time-dependent Cox regression modelling was employed to assess the effects of chemotherapy (pemetrexed and EPP), fitted as time-varying covariates, both in univariate analysis and with adjustment for important prognostic factors (fixed effects). Prognostic factors were identified using a backward selection procedure. Only variables with *P*\<0.20 in univariate analysis were included as candidate variables in the model selection procedure.

NLR was assessed as a continuous variable. The remaining continuous variables were dichotomised according to clinically relevant classification. Albumin and white cell count (WCC) were significant in univariate analysis but were omitted from the model due to a low number of available results for albumin and the relationship between WCC and NLR. Logistic regression was employed to identify predictors of long-term survival (survival double that of our median of 10 months (i.e., 20 months)).

To illustrate the impact of EPP, we utilised a proportional hazards model fitted to patients classified as good-prognosis according to EORTC prognostic scoring (in brief with two or less of the following characteristics: WBC ⩾8.3 × 10^9^ l^−1^; ECOG⩾1; histological diagnosis probable/possible; male gender; non-epithelioid histology) ([@bib12]). Extended Kaplan--Meier estimates ([@bib38]) were calculated and plotted. A sensitivity analysis of the effect of EPP was conducted using the landmark analysis ([@bib17]) for comparison with the time-dependent model results. A landmark time of 4 months was selected as the majority of EPP procedures were performed within the first 4 months. A Cox regression model was employed which assessed the effect of EPP within 4 months on survival from 4 months onwards. This method is based on non-randomised comparisons and only includes patients surviving to 4 months. In the subgroup analysis, a test for interaction in the Cox regression model was performed to ascertain whether the hazard ratio for the effect of EPP surgery on survival differed significantly between the various categories.

Finally, using Cox regression a points system (Prognostic Index (PI)) was developed by simplifying the computations of the multivariable risk model as per [@bib40]). The points system is a system that simplifies the computation of the ∑*β*X required to estimate risk from a Cox model. This is achieved by assigning integer points to each level of each risk factor so that a clinician can easily approximate ∑*β*X for a specific risk factor profile by summing integer points. The weighted points are determined by the relative magnitudes of the regression co-efficients from Cox regression. The risk estimate is then determined from a reference table, which provides risk estimates for each point total. The points system is organised around categories designed to mirror clinically meaningful risk factor states. All available clinical and demographic information was considered to derive the new PI. The final model was based on a sample size of 551 patients. The discriminatory ability of the PI was measured by calculating *C* statistics (identical to the area under the receiver operating characteristic (ROC) curve, ranging from 0 to 1). A Wilcoxon statistic ([@bib20]; [@bib23]) was calculated, which provides the same quantity as that obtained by calculating the area under the corresponding ROC curve using the trapezoidal rule. This requires forming all possible pairs of events and non-events and counting pairs in which a risk index correctly orders the pair to derive the probability of a correct ranking. Ties are scored 0.5. The association between the risk score and survival was compared with that of an existing scoring system (EORTC), which classifies patients into two groups: a good-prognosis group that corresponds to patients having 0--2 poor prognostic factors; and a poor-prognosis group that have 3--5 unfavourable factors. For the purpose of this comparison, our new scoring system was dichotomised with receiver operating characteristic analysis used to determine the optimum risk score cutoff to predict 20-month survival.

For each scoring system, the two risk groups were compared for survival duration using the log-rank test and Cox model. Kaplan--Meier curves were constructed to compare survival probabilities. Additionally, separate Kaplan--Meier curves were constructed for each of the four groups formed from unique combinations of the EORTC score (0--2, 3+) and the new PI (0--5, 6+). A Cox model that included both indexes as explanatory variables was also fitted. We could not perform a comparison to the CALGB model due to the absence of key variables in retrospective records.

SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA) was used for the analysis. R 3.0.2 and STATA 13.0 (StataCorp, College Station, TX, USA) were used for the graphics.

Results
=======

Patient characteristics
-----------------------

Data on 1121 patients diagnosed with MPM were collected. Patients were excluded from our analyses if they resided (or received medical care) outside of NSW (17%), had primary peritoneal disease (\<1%) or their basic clinical information was missing (\<1%). After applying these exclusion criteria, data on 910 patients were available for analyses representing 82% of patients registered at the DDB ([Figure 1](#fig1){ref-type="fig"}).

MPM patients were more likely to be male (90%), elderly (median age of 72 years at diagnosis), live in a major city (66%), have epithelioid histology (60%) and have an ECOG status ⩾1 (85%) ([Table 1](#tbl1){ref-type="table"}). Calretinin expression on immunohistochemistry (IHC) was available for 82% of patients, with 91% showing positive expression (97.3% in epithelioid, 94.8% in biphasic, 60% in sarcomatoid). Clinical stage at diagnosis was available for 86% of patients, with 48% having early stage and 52% advanced stage disease. In total, 41% of patients received chemotherapy: 93% of these received pemetrexed-based chemotherapy. Data concerning chemotherapy use were missing in 7% of patients. Chemotherapy utilisation increased from almost 39% to 49% during the study period as a likely consequence of the addition of pemetrexed to the Australian pharmaceutical benefits scheme (November 2007). There was no difference between chemotherapy usage in patients living in major cities in comparison to patients living in regional/remote locations (41.5% *vs* 40.7%). Radical surgery, in the form of EPP, was undergone by 6.4% of the study population. Fifty-six of the 58 (97%) of these operations were performed by a single surgeon. The 90-day mortality in this series was 3.5%. Of those patients receiving EPP, 64% underwent postoperative radiotherapy and 33% induction or adjuvant chemotherapy.

Survival analysis
-----------------

The median survival time in the whole study population was 10.0 months from diagnosis to death or last follow-up, ranging from 0 to 123.6 months. Age and gender were associated with longer survival; however, there was no clear association with other demographic variables ([Table 2](#tbl2){ref-type="table"}). Patients with the epithelioid subtype survived significantly longer than those presenting with biphasic or sarcomatoid histology (13.4 months *vs* 7.2 and 5.4 months respectively; *P*\<0.001). An ECOG status of 0 was associated with a marked improvement in survival (26.6 *vs* 9.8 months; *P*=0.015). Additional factors such as low NLR, normal WCC, normal albumin, normal haemoglobin and normal platelet counts were also associated with longer-term survival. Patients who had undergone an EPP had a median survival of 24.7 months (counted from diagnosis and 21.7 months from the date of surgery), whereas the median survival of patients who did not receive radical surgery was limited to 9.5 months. When modelled as a time-dependent variable unadjusted for other covariates, the effect of EPP on survival was significant (HR=0.41 (0.30, 0.56); *P*\<0.001). Patients who received pemetrexed-based chemotherapy had a median survival of 15.8 months from diagnosis (11.4 months from treatment) compared with 10.4 months (6.1 months from treatment) on other chemotherapy regimens (*P*=0.017 from Cox model comparing time-dependent effects). Patients who received no chemotherapy had a median survival of 6.6 months from diagnosis. The EORTC prognostic score consistent with 'low-risk\' conferred a survival advantage (14.2 *vs* 8.3 months; *P*\<0.001) in comparison to the 'high-risk\' subgroup.

Multivariate analyses
---------------------

Data from 557 patients were included in the multivariate analyses. For these analyses, only those factors with *P*\<0.20 in the univariate analysis were considered ([Table 3](#tbl3){ref-type="table"}). CT staging was not included due to limitations associated with this modality.

Multivariate analyses showed increasing age (\>70 years) and male gender had poorer survival outcomes, while ECOG status was not an independent prognostic factor. Patients presenting with a tumour with negative calretinin expression had a two-fold greater mortality risk than patients with positive calretinin IHC (HR 2.13, 95% CI 1.50, 3.02). High platelet counts (⩾400 × 10^9^ l^−1^), and low haemoglobin were also associated with an increased risk of death (HR 1.39; 95% CI 1.13, 1.70 and HR 1.27; 95% CI 1.02, 1.58, respectively). Increasing NLR (on assessment as a continuous variable) was also independently associated with poor prognosis (HR 1.04; 95% CI 1.02, 1.06). Patients who presented with non-epithelioid histological subtypes had a two-fold greater risk of mortality compared with epithelioid histology (HR 2.00; 95% CI 1.62, 2.48).

A landmark analysis of 721 patients was undertaken that compared survival in EPP and non-EPP patients from the start of the fourth month following diagnosis (when 44 of the 58 EPPs had been performed). This demonstrated a survival advantage for EPP (HR=0.42 (95% CI: 0.29--0.60); *P*\<0.001); independent of other variables ([Figure 2](#fig2){ref-type="fig"}).

Separately, we also analysed patients classified as good-prognosis according to the EORTC criteria ([@bib12]). Of the 305 patients fulfilling EORTC criteria, 32 received EPP while 273 patients did not. The EPP group had a significantly reduced mortality risk (HR=0.49 (95% CI: 0.32, 0.73; *P*\<0.001; [Figure 3](#fig3){ref-type="fig"}). Median survival in the group of patients who did not receive EPP was 13.3 months (range 0.2--109.6 months), with 29% surviving for ⩾20 months. In patients who did receive EPP, the median survival was 24.7 months from diagnosis (21.6 months from the date of surgery) and 66% survived ⩾20 months following diagnosis.

Logistic regression
-------------------

One in four patients diagnosed with MPM survived at least twice as long as the median survival time. Early stage disease, positive calretinin expression, epithelioid subtype, younger age and a normal haemoglobin level were all independently associated with prolonged survival. In this group of 'long survivors\', 66%% received chemotherapy and 16% had undergone radical surgery. It is noteworthy that a third of the group of long survivors did not receive any chemotherapy or radical surgery. Epithelioid histology, lower WCC and platelet counts, lower NLR and higher haemoglobin levels were more prominent in the long-term survivors (\>20 months) in a subgroup analysis of patients who did not receive any chemotherapy or radical surgery (*N*=455).

Finally, we derived a PI to predict the probability of longer-term survival for MPM patients based on the variables analysed in this study ([Figure 4](#fig4){ref-type="fig"}). By summing the points across these factors, it was possible to predict the probability of an individual patient to survive for \>20 months. For example, using the values in [Figure 4](#fig4){ref-type="fig"}, a male patient (1 point), aged 70--79 years (3 points), with epithelioid subtype (0 points), with a NLR of ⩾10 (2 points), had a total of 6 points, or a 22% probability of 20-month survival following a MPM diagnosis. Upon ROC analysis, the optimal cutpoint for the PI was determined ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Patients were defined as 'low risk\' if the PI yielded a score of ⩽5, with a sensitivity and specificity of 76% and 62%, respectively, for survival beyond 20 months. A *C* statistic of 0.747 was noted, suggesting moderate performance for the PI. 'High-risk\' patients were associated with a median survival of 6.6 months (HR 2.4; c.f 16.6 months in the low-risk subgroup; *P*\<0.0001; [Figure 5A](#fig5){ref-type="fig"}). A comparison of our PI with the EORTC prognostic model revealed better separation of good and poor prognosis using the PI. Furthermore, the application of the PI score to patients already separated into low- and high-risk subgroups by the EORTC score provided additional prognostic value with enhanced separation of the survival groups ([Figure 5B](#fig5){ref-type="fig"}). Conversely, the addition of the EORTC score to PI score did not provide any further improvement in prognostication. Upon analysis of variables instrumental in reallocation from high to low subgroups (and vice verse) between the EORTC and PI models, albumin, calretinin, NLR and age provided the greatest additional discriminatory information.

Discussion
==========

This series of patients with MPM who registered with the DDB reflects one of the largest series reported so far. All NSW people with asbestos exposure had access to DDB support without geographic, ethnic or financial restrictions, as long as their exposure had occurred in an occupational setting in NSW. As such, this series reflects a general MPM population with minimal selection bias.

Our study suggests that there are two distinct categories of patients with MPM. One with a rapid and fatal disease course, as is well recognised in the clinical literature, and a second group for whom survival is significantly longer. A significant proportion of the current series of patients (25%) lived at least double the median survival time of 10.0 months, a finding consistent with previous reports ([@bib43]; [@bib46]). One-third of this group of long survivors did not receive any chemotherapy or radical surgery.

Prognostic factors and risk scores have typically been derived from populations of patients who are on clinical trials or in the small group of patients who have been well enough for radical surgery and who may not be representative of the general MPM population. The factors associated with longer-term survival in unselected MPM cohorts have not been extensively studied. Previous analyses have demonstrated the role of gender, age and histological subtype as prognostic factors ([@bib2]; [@bib33]), but a lack of accurate clinical, pathological and treatment data have precluded more comprehensive analyses. We have been able to obtain most of these data for the patients included in our population-based series. Our results confirm the prognostic value of demographic variables (age and gender) and clinical and laboratory factors (histological subtype, NLR, albumin, haemoglobin and platelet counts). We have also collected evidence for factors where significance was unclear, namely calretinin expression, the effects of chemotherapy and radical surgery. In addition, we have also developed a prediction tool that may assist clinicians in identifying MPM patients likely to experience longer-term survival.

Calretinin expression has previously been found to be associated with prolonged survival in selected surgical series of MPM patients ([@bib24]). To our knowledge, this study presents the first evidence for an important association between prognosis and calretinin expression in a large, unselected MPM population. The association between positive staining and prolonged survival is of the same magnitude as the association between epitheloid subtype and prolonged survival in multivariate analysis. Patients with no calretinin expression had poor survival (median survival time of 5.5 months). However, it should be noted that the size of this specific group was relatively small (8.6% of patients tested). This observation raises the question whether calretinin may be involved in tumour growth. Recent data suggest that there is a role for calretinin in maintaining the viability and proliferation of mesothelioma cells *in vitro* and that downregulation of this target occurs when apoptosis pathways become activated ([@bib4]). Calretinin expression may also be seen as a surrogate marker for tumour differentiation ([@bib41]).

Our series shows that 41% of patients received chemotherapy. This did not differ between major cities and regional/remote locations. The percentage of patients receiving chemotherapy is comparable to another population based study in Europe demonstrating chemotherapy usage of 36% during a similar period ([@bib13]). Rates were lower still in the UK-based series where, although 37% were considered suitable for chemotherapy, 52% of patients declined its use ([@bib11]). We do, however, note an increase in chemotherapy usage after the addition of pemetrexed to the Australian Pharmaceutical Benefits Scheme (38.9--\>48.8%). Our data confirm that pemetrexed-based chemotherapy is associated with a survival benefit. [@bib43] demonstrated that administration of pemetrexed in combination with cisplatin was responsible for a significant (3-month improvement) in overall survival. In our study, a 5-month survival difference was recorded when patients with and without pemetrexed-containing regimens were compared.

EPP, the en bloc resection of the pleura and lung, is typically reserved for a group of highly selected medically fit patients with lower volume, epithelioid MPM. Retrospective and non-randomised prospective analyses of EPP studies in MPM have produced inconsistent results with survival, mortality and morbidity rates varying markedly between studies and centres ([@bib44]; [@bib47]; [@bib28]). The prospective MARS feasibility study ([@bib42]), attempting to compare EPP in combination with chemotherapy and radiotherapy to chemotherapy alone, noted a 5-month decline in overall survival in patients undergoing EPP. However, the significant recruitment difficulties, patient crossover (only 16 of the 24 patients randomised to EPP underwent surgery) and the high operative mortality (15.8%) has complicated the interpretation of the study results and induced a lively discussion about the role of EPP in MPM ([@bib36]; [@bib45]). Theoretically, EPP remains the favoured surgical procedure for optimal cytoreduction ([@bib34]), but in recent years a move to the less aggressive extended pleurectomy/decortication (also associated with median survivals of over 30 months) has occurred owing to concerns that EPP may be associated with increased morbidity/mortality as well as a reduction in the quality of life ([@bib5]; [@bib18]; [@bib8]).

In our series, 6% of patients underwent EPP. This percentage is markedly lower than in previously reported US single institution series ([@bib16]). Although palliative surgical procedures such as pleurectomy and/or decortications (P/D) were noted in the files of patients in our series, we have not included these data in our report. Absence of standardisation and variability in reporting were the main reasons for this decision. In general, however, the performance of P/D within NSW has been primarily for palliative intent. In this series, EPP patients had a survival benefit, and this benefit remained unaffected when adjustments were made for favourable prognostic factors present at diagnosis. This finding differs from a recent study in 1365 Italian patients diagnosed with MPM, where the survival advantage noted in patients receiving EPP disappeared after restricting the analyses to patients with favourable factors ([@bib6]). The inconsistency between the Italian results and our study can be explained by two factors. First, the percentage of patients undergoing EPP in our study was lower than the Italian cohort. Second, in our study one single surgeon completed 57 of the 58 EPPs, suggesting that expertise and volume--outcome associations are important. This is underlined by a 90-day mortality of 3.5%, which is markedly lower than the mortality in the MARS feasibility trial and meta-analysis ([@bib8]). The mortality percentage in this series is consistent with the percentage seen in other high-volume centres ([@bib7]). Overall, our findings suggest that, in experienced hands, EPP is a safe and potentially advantageous intervention in a highly selected group of patients.

A potential limitation of our study is that more patients were categorised as having early stage disease compared with previous studies ([@bib43]). Clinical stage is most accurately determined when PET scan or surgical staging data are available ([@bib37]). However, these interventions were only performed in a minority of patients. Instead, clinical stage as determined by CT was available for 85% of the study population. As a result, late stage disease (stages III--IV) in this study was defined as bulky pleural, nodal or metastatic disease, rather than an accurate TNM status. This is unavoidable in a population-based study with non-uniform diagnostic imaging and sometime lack of tertiary expertise. To eliminate this potential inaccuracy, we have not included CT staging in our multivariate analysis or the PI.

We can only speculate about the reasons behind prolonged survival of patients who did not receive any active treatment. Although these patients were more likely to have epithelioid histology and 'normal\' haemoglobin, white cell and platelet counts, additional factors may have played a role. In a previous study, we have pointed to the potential prognostic significance of ERCC1 and PLK1. In addition, miRNAs are thought to have an important role ([@bib25]; [@bib27]; [@bib29]), while biomarkers such as mesothelin and osteopontin may also influence survival ([@bib19]; [@bib35]). Although these biomarkers could not be assessed in this series, the performance of further studies with existing and new prognostic markers and their incorporation in prognostic scoring systems remain a priority.

Finally, we have presented a tool to select patients for intensive therapy approaches by combining prognostic factors. The tool includes two markers not included in previously published risk-prediction tools for MPM ([@bib12]; [@bib22]), namely, NLR and calretinin expression. We have not included ECOG performance status in our model as it lacked significance on multivariate analysis. Furthermore, the inclusion of a variable assessing the probability of accurate histological diagnosis is of lesser value in the modern era as guideline-driven immunohistochemical testing has eliminated much diagnostic uncertainty.

We have added newly identified factors to established prognostic factors and developed a PI that seems to have additional prognostic value over the existing EORTC model. In order to further assess this model, validation is now warranted in a large independent series of patients. Although bias-corrected estimates on the training samples can be calculated using boot-strapping, in data sets with large sample sizes and event numbers (as in our series where 96% of patients had died of the 551 used to develop the risk score), optimism in performance measures has been shown to be small and apparent estimates of model performance are attractive because of their stability ([@bib39]). As such, bootstrapping was not indicated for our final model.

In conclusion, this study has confirmed the role of a range of factors known to be associated with longer-term survival in a real-world MPM population. We also found that calretinin expression is strongly associated with survival outcomes. EPP and pemetrexed-containing chemotherapy seem also capable of inducing a survival benefit that remains distinguishable after correction for 'good prognosis\' factors. Finally, we have presented a risk score that may assist with the appropriate selection of patients for intensive (combined modality) therapy approaches.
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![**CONSORT diagram of patient recruitment.**](bjc2014478f1){#fig1}

![**Four-month landmark analysis: effect of EPP surgery within 4 months on survival after 4 months.** Analyses included up to 721 patients alive at 4 months. \*Unknown group (*N*=78) excluded from analysis as zero patients in this category underwent surgery.](bjc2014478f2){#fig2}

![**Extended Kaplan--Meier survival curves, stratified by time-varying EPP surgery status in good prognosis group (i.e., EORTC=low risk, *N*=305).** Hazard ratios and *P*-values are from a Cox regression model with a time-varying covariate.](bjc2014478f3){#fig3}

![**Probability of 20-month survival following a MPM diagnosis using risk scores based on a patient\'s demographic, diagnosticand tumour characteristics.**](bjc2014478f4){#fig4}

![**(**A**) Kaplan--Meier curves demonstrating survival according to prognostic indices (PI Score---0--5 *vs* 6+) and EORTC score (Low risk---0--2 *vs* High risk---3+).** (**B**) Survival by PI cross-classification.](bjc2014478f5){#fig5}

###### Characteristics of patients diagnosed with malignant pleural mesothelioma compensated for occupational asbestos exposure in New South Wales, 2002--2009 (*n*=910), by patient characteristics

                                                                    **Number (value)**    **%**
  ----------------------------------------------------------------- -------------------- -------
  **Demographic characteristics**                                                        
  **Sex**                                                                                
   Male                                                             92                     90
   Female                                                           818                    10
  Median age at diagnosis                                           (72 years of age)      ---
  **Smoking status**                                                                     
   Never smoker                                                     302                    33
   Ex/current smoker                                                464                    51
   Missing status                                                   144                    16
  **Asbestos exposure**                                                                  
   Median age at first exposure                                     18 years of age        ---
   Median cumulative asbestos exposure[a](#t1-fn2){ref-type="fn"}   24 years               ---
  **Geographic location at the time of diagnosis**                                       
   Major city                                                       605                    67
   (Inner or outer) Regional                                        302                    33
   Remote                                                           3                      \<1
  **Clinical and pathological characteristics**                                          
  **ECOG status**                                                                        
   0                                                                14                      2
   ⩾1                                                               776                    85
   Missing                                                          120                    14
  **Calretinin expression**                                                              
   Positive expression                                              681                    75
   Negative expression                                              64                      7
   Testing not performed                                            165                    18
  **Clinical stage at diagnosis[b](#t1-fn3){ref-type="fn"}**                             
   Early stage disease (Stages X, I--II)                            377                    42
   Late stage disease (Stages III--IV)                              404                    44
   CT data not available                                            129                    14
  **NLR**                                                                                
   \<5                                                              530                    58
   ⩾5                                                               316                    35
   Missing                                                          64                      7
  **Haemoglobin (from baseline)**                                                        
   \<1g dl^−1^                                                      211                    23
   ⩾1g dl^−1^                                                       637                    70
   Missing                                                          62                      7
  **Platelets ( × 10^9^ l^−1^)**                                                         
   \<400                                                            613                    67
   ⩾400                                                             232                    26
   Missing                                                          65                      7
  **Albumin**                                                                            
   ⩾35g dl^−1^                                                      382                    42
   \<35g dl^−1^                                                     281                    31
   Missing                                                          247                    27
  **White cell count**                                                                   
   \<8.3                                                            394                    43
   ⩾8.3                                                             453                    50
   Missing                                                          63                      7
  **Tumour characteristics**                                                             
  **Histological subtype**                                                               
   Epithelioid                                                      545                    60
   Biphasic                                                         119                    13
   Sarcomatoid                                                      153                    17
   Missing values                                                   93                     10
  **Treatment characteristics**                                                          
  **Chemotherapy**                                                                       
   Received chemotherapy                                            375                    41
   Received pemetrexed                                              344                    38
   Did not receive chemotherapy                                     474                    52
   Missing data                                                     61                      7
  **Surgery**                                                                            
   Underwent EPP                                                    59                      7
   Did not undergo EPP                                              851                    93
   Missing                                                          1                       0
  **Radiotherapy**                                                                       
   Adjuvant radiotherapy performed                                  37                      4
   Adjuvant radiotherapy not performed                              803                    88
   Missing                                                          71                      8
  **Outcome characteristics**                                                            
  Median overall survival                                           10.0 months            ---
  EORTC Prognostic Score                                                                   ---
   \<3                                                              305                    34
   ⩾3                                                               468                    51
   Missing                                                          137                    15

Abbreviations: ECOG=Eastern Cooperative Oncology Group; EORTC=European Organisation for Research and Treatment of Cancer; EPP=extrapleural-pneumonectomy; NLR=neutrophil--lymphocyte ratio.

Estimated using data of a patients\' first age at asbestos exposure and occupational history.

Categorised by clinical investigators on this study using CT scan data grouped by the AJCCC criteria.

###### Median survival time in months for patients diagnosed with malignant pleural mesothelioma compensated for occupational asbestos exposure in New South Wales, 2002--2009, by patient characteristics

                                                               **Median survival in months**   **Difference (Log-rank *P*-value)**
  ------------------------------------------------------------ ------------------------------- -------------------------------------
  **Demographic characteristics**                                                              
  **Sex**                                                                                      
   Male                                                        9.9                             \<0.001
   Female                                                      12                               
  **Age at diagnosis**                                                                         
   \<70 years of age                                           13.5                            \<0.001
   ⩾70 years of age                                            8.5                              
  **Smoking status**                                                                           
   Never smoker                                                10                              0.99
   Ex/current smoker                                           10.6                             
  **Asbestos exposure[a](#t2-fn2){ref-type="fn"}**                                             
   \<18 years of age at first asbestos exposure                10.9                            0.09
   ⩾18 years of age at first asbestos exposure                 9.4                              
   \<24 years of cumulative asbestos exposure                  10.4                            0.22
   ⩾24 years of cumulative asbestos exposure                   9.5                              
  **Geographic location at the time of diagnosis**                                             
   Major city                                                  10.6                            0.162
   (Inner or outer) Regional/remote                            8.8                              
  **Clinical and pathological characteristics**                                                
  **Calretinin expression**                                                                    
   Positive expression                                         10.9                            \<0.001
   Negative expression                                         5.5                              
  **Clinical stage at diagnosis[b](#t2-fn3){ref-type="fn"}**                                   
   Early stage disease (Stages X, I--II)                       12.9                            \<0.001
   Late stage disease (Stages III--IV)                         8.4                              
  **NLR**                                                                                      
   \<5                                                         11.9                            \<0.001
   ⩾5                                                          7.5                              
  **Haemoglobin (from baseline)**                                                              
   \<1g dl^−1^                                                 16.4                            \<0.001
   ⩾1g dl^−1^                                                  8.8                              
  **Platelets ( × 10^9^ l^−1^)**                                                               
   \<400                                                       11.5                            \<0.001
   ⩾400                                                        7.2                              
  **Albumin**                                                                                  
   ⩾35g dl^−1^                                                 13                              \<0.001
   \<35g dl^−1^                                                6.7                              
  **White cell count**                                                                         
   \<8.3                                                       12.9                            \<0.001
   ⩾8.3                                                        8.4                              
  **Tumour characteristics**                                                                   
  **Histological subtype**                                                                     
   Epithelioid                                                 13.3                            \<0.001
   Non-epithelioid                                             6.2                              
  ECOG                                                                                         0.015
   0                                                           27.4                             
   ⩾1                                                          9.7                              
  EORTC                                                                                        \<0.0001
   Low risk: 0--2                                              14                               
   High risk: ⩾3                                               8.2                              

Abbreviations: ECOG=Eastern Cooperative Oncology Group; EORTC=European Organisation for Research and Treatment of Cancer; NLR=neutrophil--lymphocyte ratio.

Estimated using data of a patients\' first age at asbestos exposure and occupational history.

Categorised by clinical investigators on this study using CT scan data grouped by the AJCCC criteria.

###### Hazard rate ratios for patients diagnosed with malignant pleural mesothelioma compensated for occupational asbestos exposure in New South Wales, 2002--2009, (*n*=557), by patient characteristics

                                                   **Hazard ratio**   **95% confidence interval**  ***P*-value**
  ----------------------------------------------- ------------------ ----------------------------- ---------------
  **Demographic characteristics**                                                                  
  **Sex**                                                                                          
   Male                                                  1.52                 1.12--2.07           0.008
   Female                                                 1                                         
  **Age at diagnosis**                                                                             
   \<70 years of age                                      1                                         
   \>70 years of age                                     1.4                  1.15--1.69           \<0.001
  **Clinical and pathological characteristics**                                                    
  **Calretinin expression**                                                                        
   Positive expression                                    1                                         
   Negative expression                                   2.13                 1.50--3.02           \<0.001
  **NLR**                                                                                          
   (Continous variable/increments of 1)                  1.04                 1.02--1.06           \<0.001
  **Haemoglobin (from baseline)**                                                                  
   \<1g dl^−1^                                            1                                         
   ⩾1g dl^−1^                                            1.27                 1.02--1.58           0.031
  **Platelets ( × 10^9^ l^−1^)**                                                                   
   \<400                                                  1                                         
   ⩾400                                                  1.39                 1.13--1.70           0.0015
  **ECOG**                                                                                         
   0                                                      1                                         
   ⩾1                                                    1.34                 0.71--2.52           0.37
  **Tumour characteristics**                                                                       
  **Histological subtype**                                                                         
   Epithelioid                                            1                                         
   Non-epithelioid                                       2.0                  1.62--2.48           \<0.001
   Unknown histological subtype                          1.2                  0.87--1.65           0.26
  **Treatment characteristics**                                                                    
  **Chemotherapy**                                                                                 
   Received pemetrexed                                   0.94                 0.78--1.13           0.49
   Did not receive chemotherapy                           1                                         
  **Surgery**                                                                                      
   Surgical intervention                                 0.61                 0.42--0.89           0.011
   No surgical intervention                               1                                         

Abbreviations: ECOG=Eastern Cooperative Oncology Group; NLR=neutrophil--lymphocyte ratio.
